Cocrystal Pharma Completes Dosing in Phase 1b Human Challenge Trial of Oral Norovirus Antiviral CDI-988
核心洞察
Cocrystal Pharma has completed dosing the last participant in a placebo-controlled Phase 1b human challenge study of CDI-988, an oral norovirus protease (搜索) inhibitor, at Emory University School of Medicine.
The trial uses the well-characterized Snow Mountain Virus strain and enrolled 40 subjects in isolated units, with symptoms and viral load as clear endpoints.
CDI-988 holds FDA fast track designation for norovirus (搜索) treatment and prophylaxis, with preliminary results expected in late 2026 or early 2027.
Cocrystal Pharma has completed dosing of the final participant in a placebo-controlled Phase 1b human challenge study of CDI-988, an oral norovirus protease (搜索) inhibitor, conducted at Emory University School of Medicine. The company expects preliminary results in late 2026 or early 2027, according to James Sapirstein, who joined Cocrystal as CEO in June.
CDI-988 has received FDA fast track designation for both norovirus (搜索) treatment and prophylaxis. The candidate represents a distinct development strategy in a field where vaccine approaches have recently stumbled: Moderna reported in July that its norovirus vaccine candidate, mRNA-1403, fell short of the statistical criteria for early success at a Phase 3 interim analysis and said it will enroll an additional cohort, while HilleVax, a Takeda Pharmaceuticals (搜索) spinout, failed to meet its primary efficacy endpoint in a mid-stage study in infants two years earlier.
A Deliberately Narrow Strain Strategy
Cocrystal's approach differs from prior norovirus (搜索) programs not only because its candidate is an antiviral rather than a vaccine, but because it targets a single, well-characterized strain in its challenge study.
"In the past, I think other companies have gone after the full boat of norovirus (搜索) [strains] and have not been successful. We're going after a very specific strain [in our challenge study]. And if that works, we'll go after the other strains," Sapirstein said, adding that the company's platform, which draws on the expertise of Nobel laureate and company chairman Roger Kornberg, allows for such customization.
The challenge study evaluates CDI-988 against the Snow Mountain Virus strain. Sam Lee, Ph.D., Cocrystal's president and chief scientific officer, said the strain was selected based on a publication by Dr. Nadine Rouphael and Emory University that carefully examined the titer needed to create disease, as well as the inoculum's availability, stability, and infectivity rate. "It's been really well characterized in terms of virus stock," Lee said.
Trial Design and the Infectivity Question
The study recruited 40 subjects, with 10 isolated units per site staffed and monitored continuously by investigators. Once the norovirus (搜索) inoculum is introduced, symptoms develop in about two days and last about five days — the key window for evaluating symptoms and quantifying viral load in stool and emesis samples. After five days, the immune system clears the illness, and subjects are kept for an additional week to ensure no acute gastroenteritis, with the goal of preventing any contamination that could lead to outbreaks.
"The advantage of a human challenge study is determining the efficacy of the treatment in a really well-controlled environment," Lee said. "So, it's a small study. However, the endpoints are really clear: symptoms and viral load."
Lee emphasized that infectivity rate is the pivotal variable in such small trials. "Because this is a small study, if you don't establish infectivity rate, you may not get meaningful data," he said. "If you achieve a poor infectivity rate, say 20% or 30%, then everything becomes a challenging issue." In the first cohort, Cocrystal confirmed the infectivity rate before introducing the drug to a study group.
If the protocol's infectivity target is not met, Lee said the company would pause the study and investigate whether to increase the inoculum, in consultation with regulators. "It's not good clinical practice to recruit healthy volunteers, create the disease, and not have a meaningful outcome," he said.
Inoculum Supply as a Development Bottleneck
Lee identified the viral inoculum itself as the trial's real bottleneck. Few contract research organizations worldwide conduct norovirus (搜索) clinical trials and claim to have the best inoculum in terms of stability, viral titer, and FDA approval, he said, and access to qualified inoculum for biotech, pharmaceutical, and academic sponsors remains constrained.
Cocrystal's Snow Mountain Virus stock is NIH-funded and was generated by Emory University and the University of North Carolina, which isolated the sample from a patient and scaled it up into stock virus. Those institutions contacted the FDA to obtain approval to use the stock virus in Cocrystal's study, a process managed by a different FDA division. Cocrystal also interacted directly with the FDA for the Phase 1b trial, which Lee described as smooth, and has conducted a challenge study in the U.K. through its CRO, which dealt with the MHRA.
Disease Burden and Positioning
Norovirus (搜索) causes an estimated 685 million illnesses annually and $60 billion worldwide in healthcare costs and lost productivity, according to the article's cited figures. In the U.S., the CDC estimates about 109,000 hospitalizations and roughly 900 deaths each year, mostly among older adults. No specific medicine exists to treat norovirus; care focuses on replacing lost fluids and managing symptoms, including with medicines like Imodium.
"What we hear from patients is that norovirus (搜索) won't kill you, but you wish it did," Sapirstein said, describing the virus as "just too smart" — a difficulty he said shapes the company's development strategy.
On commercial positioning, Sapirstein said the drug's safety profile could determine its eventual access model. "If it turns out to be an extremely safe drug, it can be an ethical drug for a couple years, and then we [could] talk to the FDA about maybe going OTC so that it could be stocked around the world," he said. "Because even if you have 40% or 50% efficacy, do you really want to just have it available by prescription when it's really needed around the world?"
Sapirstein, who joined Cocrystal after leading the global launch of the HIV drug tenofovir (Viread) at Gilead Sciences and holding senior positions at Bristol Myers Squibb and Serono Laboratories, as well as prior CEO roles at Tobira Therapeutics and Contravir Pharmaceuticals, said he aims to bring operational and commercial expertise to a historically science-focused company. "This is a microcap company at this point. We're trying to build it out, and I'm trying to turn the story around," he said, adding that he is interested in dealmaking, whether acquiring companies or assets, or being acquired.